arrow
E

Esther Mena

national institutes of health
H指数:36
被引数:5,118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial

Tra贝替丁和低剂量伊立替康靶向EWS::FLI1在尤因肉瘤中的作用: 1/2期试验

2026-04-160
PRE
Artificial intelligence-based lesion characterization and outcome prediction of prostate cancer on [18F]DCFPyL PSMA imaging

基于人工智能的[18F]DCFPyL PSMA成像在前列腺癌病灶特征描述和预后预测中的应用

2025-11-050
PRE
A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

一项关于达鲁珠单抗、卡非佐米和地塞米松(DKd)在高危冒烟型多发性骨髓瘤患者中的2期适应性研究

BLOOD
IF23.1
2024-11-050
PRE
Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)

伦伐替尼(L)和索拉非尼(S)在晚期或不可切除的肝细胞癌(uHCC)患者(pts)中的应用:一项国际、多中心、IV期研究(STELLAR)。

2024-09-010
PRE
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024-06-205
OAAI
Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study

基于深度学习的前列腺癌分期ct骨病变检测与分类的发展研究

2024-06-010
PRE
Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI

通过MRI在18F-DCFPyL PSMA PET/CT上减少由于前列腺尿道中的尿停滞而导致的假阳性

2024-04-191
PRE
Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy
2023-10-112
OAAI